Ipsen Appoints Olivia Brown to Lead Neurotoxins Division
In an exciting development, Ipsen, a global leader in specialty care, has strengthened its Executive Leadership Team with the addition of Olivia Brown as the Executive Vice-President and Global Head of Neurotoxins. This strategic appointment is effective from April 1, and marks a significant step in advancing Ipsen's innovative approach within the neurotoxins market.
The Role of Olivia Brown
Olivia joins Ipsen with over two decades of distinguished experience in pharmaceuticals and medical aesthetics. Her previous role at Novartis saw her spearheading the development of a new therapeutic area focusing on Allergy & Immunology. Additionally, her expertise was honed during her tenure at Merz Aesthetics and Galderma, where she was integral in driving market expansion for neurotoxins.
Her Vision for Neurotoxins
In her new capacity, Olivia will guide the neurotoxins franchise at Ipsen, overseeing strategies that encompass both therapeutic and aesthetic applications. CEO David Loew expressed excitement about Olivia joining the team, emphasizing her extensive experience in global strategy and commercialization that will propel the company towards new avenues of growth and innovation.
Innovating in Neurotoxins
With over 30 years of experience in the neurotoxins sector, Ipsen has solidified its status as a frontrunner in neurosciences. The company's commitment to innovation is exemplified by its impressive pipeline, including the promising Long-Acting Neuro-Toxine (LANT) program. This groundbreaking therapy is designed to effectively bind to receptors associated with BoNT B and deliver the active light chain of BoNT A, demonstrating significant potential for improved patient outcomes through longer-lasting effects and reduced frequency of injections.
Market Impact
As the neurotoxins market continues to evolve rapidly, Olivia’s leadership arrives at a pivotal moment. Her extensive background will enable Ipsen to capitalize on growth opportunities and enhance its competitive edge in a dynamic landscape. The potential of the LANT AB program reflects Ipsen's dedication to delivering advanced solutions that align with patient needs and expectations.
About Ipsen
Ipsen is a global biopharmaceutical company focused on transforming patient care across key therapeutic areas, including Oncology, Rare Diseases, and Neurosciences. With nearly a century of development expertise, Ipsen’s global presence spans over 40 countries, ensuring that innovative medicines reach patients in more than 80 countries. As an organization listed on Euronext under the ticker symbol IPN, Ipsen is committed to driving healthcare advancements.
Get in Touch with Ipsen
Investors
- Alina Levchuk | +41 79 572 8712 | alina.levchuk@ipsen.com
- Nicolas Bogler | +33 6 52 19 98 92 | nicolas.bogler@ipsen.com
Media
- Sally Bain | +1 857 320 0517 | sally.bain@ipsen.com
- Anne Liontas | +33 7 67 34 72 96 | anne.liontas.ext@ipsen.com
Frequently Asked Questions
Who is the new Executive Vice-President at Ipsen?
Olivia Brown has been appointed as the new Executive Vice-President and Global Head of Neurotoxins.
When does Olivia start her role at Ipsen?
Her role becomes effective on April 1.
What experience does Olivia Brown bring to Ipsen?
Olivia has over two decades of experience in pharmaceuticals and has previously held senior roles at Novartis, Merz Aesthetics, and Galderma.
What is the focus of Ipsen's neurotoxins franchise?
The neurotoxins franchise focuses on both therapeutic and aesthetic applications, aiming to advance innovation in the field.
What is LANT and its significance?
LANT is Ipsen's Long-Acting Neuro-Toxine program, designed for improved patient outcomes through longer-lasting effects, potentially reducing injection frequency.
